From another point of view, since it has recently been revealed that tumor mutation load is one of the factors determining the response to immune checkpoint inhibitors (ICIs) [36], the POLQ expression level could determine the response to ICIs via defying the number of tumor somatic mutations, and ICIs could be more effective against LACs exhibiting POLQ overexpression. The gene discussed is POLQ; the disease is neoplasm.